Stay updated on Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial

Sign up to get notified when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The clinical trial record for fruquintinib and sintilimab in refractory metastatic colorectal cancer is displayed, including its eligibility criteria, treatment plan, primary outcome, locations, and study dates.
    Difference
    42%
    Check dated 2026-11-08T13:42:19.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer now identifies the ClinicalTrials.gov site revision as v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-11-01T14:54:12.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A banner announces an NIH website transition and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content during the transition.
    Difference
    1%
    Check dated 2026-10-25T13:49:13.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T14:15:07.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changes from v3.7.0 to v3.7.1 while the study page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T14:57:08.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page previously displayed a 403 Forbidden error, and now presents the full study record for NCT04695470, including sections on study overview, eligibility criteria, design details, interventions (Fruquintinib with Sintilimab), primary outcomes, enrollment, and locations.
    Difference
    43%
    Check dated 2026-09-27T20:31:43.000Z thumbnail image

Stay in the know with updates to Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.